{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T09:21:50Z","timestamp":1789204910602,"version":"build-2803163510"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"16","license":[{"start":{"date-parts":[[2021,10,21]],"date-time":"2021-10-21T00:00:00Z","timestamp":1634774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,10,21]],"date-time":"2021-10-21T00:00:00Z","timestamp":1634774400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1007\/s40265-021-01619-6","type":"journal-article","created":{"date-parts":[[2021,10,21]],"date-time":"2021-10-21T11:02:58Z","timestamp":1634814178000},"page":"1937-1944","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":66,"title":["Difelikefalin: First Approval"],"prefix":"10.1007","volume":"81","author":[{"given":"Emma D.","family":"Deeks","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,21]]},"reference":[{"issue":"5","key":"1619_CR1","doi-asserted-by":"publisher","first-page":"555","DOI":"10.2340\/00015555-1353","volume":"92","author":"NQ Phan","year":"2012","unstructured":"Phan NQ, Lotts T, Antal A, et al. Systemic kappa opioid receptor agonists in the treatment of chronic pruritus: a literature review. Acta Derm Venereol. 2012;92(5):555\u201360.","journal-title":"Acta Derm Venereol"},{"issue":"1","key":"1619_CR2","doi-asserted-by":"publisher","first-page":"e23","DOI":"10.1016\/j.ddtec.2011.07.007","volume":"9","author":"JV Aldrich","year":"2011","unstructured":"Aldrich JV, McLaughlin JP. Opioid peptides: potential for drug development. Drug Discov Today Technol. 2011;9(1):e23\u201331.","journal-title":"Drug Discov Today Technol"},{"issue":"4","key":"1619_CR3","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1111\/jcpt.12404","volume":"41","author":"A Albert-Vartanian","year":"2016","unstructured":"Albert-Vartanian A, Boyd MR, Hall AL, et al. Will peripherally restricted kappa-opioid receptor agonists (pKORAs) relieve pain with less opioid adverse effects and abuse potential? J Clin Pharm Ther. 2016;41(4):371\u201382.","journal-title":"J Clin Pharm Ther"},{"key":"1619_CR4","doi-asserted-by":"publisher","first-page":"151","DOI":"10.2147\/DHPS.S28829","volume":"5","author":"N Vadivelu","year":"2013","unstructured":"Vadivelu N, Huang Y, Mirante B, et al. Patient considerations in the use of tapentadol for moderate to severe pain. Drug Healthc Patient Saf. 2013;5:151\u20139.","journal-title":"Drug Healthc Patient Saf."},{"issue":"6","key":"1619_CR5","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1093\/bja\/aen094","volume":"100","author":"KT Pattinson","year":"2008","unstructured":"Pattinson KT. Opioids and the control of respiration. Br J Anaesth. 2008;100(6):747\u201358.","journal-title":"Br J Anaesth"},{"issue":"6","key":"1619_CR6","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1097\/ALN.0b013e318238bba6","volume":"115","author":"R Al-Hasani","year":"2011","unstructured":"Al-Hasani R, Bruchas MR. Molecular mechanisms of opioid receptor-dependent signaling and behavior. Anesthesiology. 2011;115(6):1363\u201381.","journal-title":"Anesthesiology"},{"key":"1619_CR7","unstructured":"Cara Therapeutics. Korsuva\u2122 (difelikefalin) injection, for intravenous use: US prescribing information. 2021. https:\/\/korsuva.com. Accessed 25 Aug 2021."},{"key":"1619_CR8","unstructured":"Cara Therapeutics, Vifor Pharma. Vifor Pharma and Cara Therapeutics announce U.S. FDA approval of Korsuva\u2122 injection for the treatment of moderate to severe pruritus in hemodialysis patients [media release]. 24 Aug 2021. https:\/\/www.viforpharma.com."},{"key":"1619_CR9","unstructured":"Unigene Laboratories Inc. Unigene announces manufacturing and clinical supply agreement with Cara Therapeutics for phase 1 study of novel kappa receptor agonist [media release]. 20 May 2011. http:\/\/www.unigene.com."},{"key":"1619_CR10","unstructured":"Cara Therapeutics Inc and Chong Kun Dang Pharmaceutical Corporation. Cara Therapeutics licenses novel kappa opioid agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation for South Korean market [media release]. 3 May 2012. http:\/\/www.caratherapeutics.com."},{"key":"1619_CR11","unstructured":"Cara Therapeutics Inc and Maruishi Pharmaceutical Co Ltd. Cara Therapeutics enters Into development and commercial alliance with Maruishi for novel kappa opioid agonist, CR845, in Japan [media release]. 29 Apr 2013. http:\/\/www.caratherapeutics.com."},{"key":"1619_CR12","unstructured":"Enteris BioPharma. Enteris BioPharma oral formulation progresses into phase 2 study with Cara Therapeutics' CR845 [media release]. 14 Jul 2015. http:\/\/www.enterisbiopharma.com."},{"key":"1619_CR13","unstructured":"Kissei Pharmaceutical and Maruishi Pharmaceutical Co Ltd. Kissei and Maruishi to collaborate for development and sales\/marketing of kappa opioid receptor agonist, \"MR13A9\", in Japan [media release]. 13 Mar 2017. http:\/\/www.kissei.co.jp."},{"key":"1619_CR14","unstructured":"Vifor Fresenius Medical Care Renal Pharma and Cara Therapeutics. VFMCRP and Cara Therapeutics to develop and commercialise CR845 injection for chronic kidney disease-associated pruritus [media release]. 23 May 2018. http:\/\/www.viforpharma.com."},{"key":"1619_CR15","unstructured":"Enteris BioPharma. Enteris BioPharma and Cara Therapeutics enter into licensing agreement for Peptelligence\u00ae to advance development of oral Korsuva\u2122 [media release]. 21 Aug 2019. http:\/\/www.enterisbiopharma.com."},{"key":"1619_CR16","unstructured":"Vifor Pharma, Cara Therapeutics. Vifor Pharma and Cara Therapeutics sign US license agreement for i.v. Korsuva\u2122* to treat dialysis patients with pruritus [media release]. 20 Oct 2020. www.viforpharma.com."},{"key":"1619_CR17","unstructured":"Cara Therapeutics. Securities and Exchange Commission: annual report on Form 10-K. 2020. https:\/\/ir.caratherapeutics.com\/static-files\/619cd29f-cdcc-4a47-be0b-ca3f3b7bb033. Accessed 30 Aug 2021."},{"key":"1619_CR18","unstructured":"Gardell LR, Spencer RH, Chalmers DT, et al. Preclinical profile of CR845: a novel, long-acting peripheral kappa opioid receptor agonist [poster]. In: International Association for the Study of Pain 2008."},{"key":"1619_CR19","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13042","author":"ER Viscusi","year":"2021","unstructured":"Viscusi ER, Torjman MC, Munera CL, et al. Effect of difelikefalin, a selective kappa opioid receptor agonist, on respiratory depression: a randomized, double-blind, placebo-controlled trial. Clin Transl Sci. 2021. https:\/\/doi.org\/10.1111\/cts.13042.","journal-title":"Clin Transl Sci"},{"key":"1619_CR20","unstructured":"Cara T. Cara Therapeutics announces summary data from phase 1 trial of oral CR845 in hemodialysis patients with chronic kidney disease [media release]. 12 Jul 2017. http:\/\/ir.caratherapeutics.com."},{"issue":"3","key":"1619_CR21","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1056\/NEJMoa1912770","volume":"382","author":"S Fishbane","year":"2020","unstructured":"Fishbane S, Jamal A, Munera C, et al. A phase 3 trial of difelikefalin in hemodialysis patients with pruritus. N Engl J Med. 2020;382(3):222\u201332.","journal-title":"N Engl J Med"},{"issue":"Suppl","key":"1619_CR22","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1681\/ASN.20203110S122d","volume":"31","author":"TD Wooldridge","year":"2020","unstructured":"Wooldridge TD, McCafferty K, Schoemig M, et al. Efficacy and safety of difelikefalin for moderate-to-severe CKD-associated pruritus: a global phase 3 study in hemodialysis patients (KALM-2) [abstract FR-OR24 plus oral presentation]. J Am Soc Nephrol. 2020;31(Suppl):22\u20133.","journal-title":"J Am Soc Nephrol"},{"key":"1619_CR23","doi-asserted-by":"crossref","unstructured":"Topf J, Wen W, Munera C, et al. Efficacy of difelikefalin in patients with moderate-to-severe chronic kidney disease\u2013associated pruritus: pooled subgroup analysis of KALM-1 and KALM-2 [abstract and poster 233]. In: National Kidney Foundation 2021 Spring Clinical Meeting.","DOI":"10.25251\/skin.5.supp.77"},{"key":"1619_CR24","doi-asserted-by":"crossref","unstructured":"Fishbane S, Wen W, Munera C, et al. Long-term safety and efficacy of difelikefalin in patients with chronic kidney disease\u2013associated pruritus: analysis from KALM-1 and KALM-2 [abstract and poster 207]. In: National Kidney Foundation 2021 Spring Clinical Meeting.","DOI":"10.25251\/skin.5.supp.75"},{"issue":"Suppl 1","key":"1619_CR25","first-page":"i16","volume":"36","author":"D Weiner","year":"2021","unstructured":"Weiner D, Menzaghi F, Wen W, et al. An open-label, multicenter study to evaluate the safety and effectiveness of intravenous difelikefalin in patients with moderate-to-severe CKD\u2013associated pruritus undergoing hemodialysis [abstract no. FC022 and presentation]. Nephrol Dialysis Transplant. 2021;36(Suppl 1):i16\u20137.","journal-title":"Nephrol Dialysis Transplant."},{"issue":"5","key":"1619_CR26","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.ekir.2020.01.006","volume":"5","author":"S Fishbane","year":"2020","unstructured":"Fishbane S, Mathur V, Germain MJ, et al. Randomized controlled trial of difelikefalin for chronic pruritus in hemodialysis patients. Kidney Int Rep. 2020;5(5):600\u201310.","journal-title":"Kidney Int Rep."},{"key":"1619_CR27","unstructured":"Cara Therapeutics Inc. Cara Therapeutics announces positive results from phase 2 trial in uremic pruritus [media release]. 23 Jul 2015. http:\/\/www.caratherapeutics.com."},{"issue":"5","key":"1619_CR28","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1053\/j.ajkd.2020.03.006","volume":"75","author":"G Yosipovitch","year":"2020","unstructured":"Yosipovitch G, Awad A, Spencer R, et al. Efficacy and safety of oral difelikefalin in stage 3\u20135 chronic kidney disease patients with moderate-to-severe pruritus: a response analysis from a randomized, placebo-controlled, phase 2 trial [abstract no. 4]. Am J Kidney Dis. 2020;75(5):820.","journal-title":"Am J Kidney Dis"},{"key":"1619_CR29","unstructured":"Cara Therapeutics. Cara Therapeutics announces topline results from KARE phase 2 dose-ranging trial of oral Korsuva\u2122 in atopic dermatitis patients with moderate-to-severe pruritus [media release]. 29 Apr 2021. http:\/\/www.caratherapeutics.com."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-021-01619-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-021-01619-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-021-01619-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T11:43:33Z","timestamp":1725968613000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-021-01619-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,21]]},"references-count":29,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["1619"],"URL":"https:\/\/doi.org\/10.1007\/s40265-021-01619-6","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,21]]},"assertion":[{"value":"21 October 2021","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Emma Deeks is a contracted employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability"}}]}}